FDA Approves Danziten, a Novel Nilotinib Formulation Without Mealtime Restrictions, for CML
核心洞察
The FDA has approved Danziten (nilotinib), a new formulation for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) without mealtime restrictions.
Danziten offers equivalent efficacy to Tasigna but with improved bioavailability, allowing for a lower dose and eliminating the need for fasting, potentially improving patient adherence.
The approval covers adult patients with newly diagnosed Ph+ CML in chronic phase and those resistant or intolerant to prior therapy, including imatinib.
Azurity Pharmaceuticals (搜索) has received FDA approval for Danziten (nilotinib), a novel formulation indicated for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). This includes newly diagnosed patients in the chronic phase, as well as those with chronic or acute phase CML resistant or intolerant to prior therapies, including imatinib. The key advantage of Danziten is that it does not require fasting, unlike the original nilotinib formulation, Tasigna.
Overcoming Mealtime Restrictions
Tasigna, while effective, has specific fasting requirements due to variable bioavailability that increases significantly when taken with food. This can lead to QT interval (搜索) prolongation and potential cardiotoxicity if not taken in a fasted state. Richard Blackburn, CEO of Azurity Pharmaceuticals (搜索), stated that Danziten offers equivalent efficacy to Tasigna but without the fasting requirements, liberating CML patients from mealtime restrictions.
Improved Bioavailability and Adherence
Danziten is re-engineered to provide consistent pharmacokinetics, eliminating clinically significant differences in nilotinib exposure regardless of fasting state or meal type. This improved bioavailability allows for a lower dose while maintaining the proven efficacy of nilotinib. Optimal tyrosine kinase inhibitor (TKI) therapy can lead to deep molecular responses and potentially treatment-free remission, with life expectancy for responding CP-CML patients approaching that of the general population. By removing fasting requirements, Danziten has the potential to improve patient adherence to treatment.
Availability and Patient Support
Danziten will be available in the coming weeks through Biologics by McKesson and Limited Specialty Distribution. Azurity will offer patient support through DanzitenCONNECT, a comprehensive program that includes Prior Authorization support and Benefits Investigation, a free first month of Danziten, a co-pay program, and a Patient Assistance Program (PAP).